Enhanced Biological Regeneration Simulator (EBRS)
A Phase I/II Clinical Trial Protocol for the Enhanced Biological Regeneration Simulator (EBRS)for Advanced Regeneration of the Adult Upper Extremity
SECTION 1: EXECUTIVE SUMMARY AND PROTOCOL OVERVIEW
1.1. Protocol Identification, Amendments, and Signatures
Title: A Phase I/II, Open-Label, Single-Arm Study to Determine the Safety, Feasibility, and Preliminary Efficacy of the Enhanced Biological Regeneration Simulator (EBRS) for Advanced Regeneration of the Adult Upper Extremity.
This protocol describes an adaptive Phase I/II interventional clinical trial designed to assess a novel combination product treatment for severe upper limb loss.1 The trial aims to initially establish the safety profile and maximum tolerated biophysical stimulation protocol (Phase I) and subsequently confirm the biological feasibility of complex tissue formation (Phase II). The protocol adheres strictly to the principles and objectives of Good Clinical Practice (GCP) guidelines, specifically referencing the framework outlined by ICH E6 (R2/R3).3 Key identifying information, including the designated EudraCT/ClinicalTrials.gov Identifier and the final signatures of the Principal Investigator, Co-Investigators, and Sponsor representatives, will be appended upon regulatory submission.
1.2. Study Rationale and Background on Adult Arm Regeneration
Severe traumatic amputation proximal to the wrist presents a critical clinical challenge, leading to profound functional impairment that is inadequately addressed by current standard-of-care options, including sophisticated prosthetics or allograft transplantation.4 Allograft transplantation introduces a significant, often lifelong, burden of immunosuppression, while prosthetics fail to fully restore native dexterity, sensory feedback, and intrinsic body schema.4 There exists an immense, unmet need for a therapeutic intervention capable of achieving true biological regeneration of complex limb structures.
The Enhanced Biological Regeneration Simulator (EBRS) is hypothesized to address this gap by moving beyond passive tissue engineering toward actively guided cellular and structural reconstruction. The EBRS is a sophisticated, bio-interactive combination product that integrates temporary structural support with an active stimulation environment designed to promote directed tissue formation. The core hypothesis posits that the EBRS can successfully induce and sustain directed cellular migration, angiogenesis, myogenesis, and targeted peripheral axon guidance across the severe amputation plane, thereby achieving functional, durable, and integrated biological regeneration of the missing upper extremity segment. The selection of an adaptive Phase I/II design is necessitated by the unprecedented nature of human whole-limb regeneration, requiring sequential confirmation of safety/dose determination (Phase I) before proceeding to feasibility and early efficacy assessment (Phase II).2
1.3. Regulatory Status and Combination Product Designation
The investigational product, the EBRS, is fundamentally classified as a complex combination product.5 It integrates multiple constituent parts: a proprietary electromechanical device (the simulator and structural scaffold), a biological component (autologous or processed cellular and tissue-based products, HCT/Ps, potentially mesenchymal stem cells), and potentially systemic or local drug components (growth factors, anti-inflammatory agents).5 The regulatory strategy is highly dependent upon the determination of the Primary Mode of Action (PMOA).6
The ultimate therapeutic outcome sought—the formation of functional, vascularized, and innervated living tissue—is mediated primarily by the regenerative cellular response, which is actively directed by the simulator’s biophysical cues. Consequently, the PMOA is defined as Biologic/Tissue Engineering, positioning the Center for Biologics Evaluation and Research (CBER) as the proposed Lead Regulatory Center.6 While CBER serves as the lead, the protocol and all manufacturing processes must explicitly satisfy the Current Good Manufacturing Practice (CGMP) requirements applicable to combination products, which entails adherence to 21 Code of Federal Regulations (CFR) Part 4, addressing both the device quality system and the stringent HCT/P regulations.5 Given that this therapy is intended to treat a serious condition (major limb loss) using a regenerative medicine therapy (cell therapy/tissue engineering product), the sponsor is actively pursuing Regenerative Medicine Advanced Therapy (RMAT) designation to utilize expedited development and review pathways.7
The table below summarizes the critical regulatory strategy employed for the EBRS.
Table 1: EBRS Regulatory Classification and Assignment Strategy
Regulatory Element | Classification for EBRS | Justification/Rationale |
Product Type | Combination Product (Device/Biologic/Drug) | Integrates device hardware (Simulator/Scaffold) with Biologic components (Autologous Stem Cells/HCT/Ps). Adherence to 21 CFR Part 4 (CGMP requirements) is mandatory.5 |
Primary Mode of Action (PMOA) | Biologic/Tissue Engineering | The desired clinical effect is driven by the directed cellular and tissue reconstruction.6 |
Proposed Lead Center (FDA) | Center for Biologics Evaluation and Research (CBER) | Assignment based on the PMOA.7 |
Designation Potential | Regenerative Medicine Advanced Therapy (RMAT) | Intended to treat a serious or life-threatening condition (major limb loss).7 |
SECTION 2: INVESTIGATIONAL PRODUCT (EBRS) DESCRIPTION
2.1. EBRS Components and Mechanism of Action
The EBRS represents a highly complex therapeutic system. It is composed of both an internal, biocompatible structural scaffold and an external, proprietary bioreactor/simulator unit. The Device Component, which includes the scaffold, provides immediate physical support and controlled tension necessary for tissue architecture maintenance, while the external unit generates a precisely modulated biophysical signal, such as a proprietary Pulsed Electro-Magnetic Field (PEMF), designed to guide tissue patterning and differentiation.
The Biologic Component consists of autologous Mesenchymal Stem Cells (MSCs) and pre-loaded, derived growth factors, such as Vascular Endothelial Growth Factor (VEGF) and various neurotrophins.2 These components are integrated directly into the scaffold material prior to implantation. The overall therapeutic mechanism relies on the synergy between the physical and biological cues: the EBRS is hypothesized to recruit endogenous progenitor cells from the remaining limb stump and, in coordination with the delivered MSCs and growth factors, actively guide the highly organized formation of all complex structures—including bone, skeletal muscle fibers, macro/microvasculature, and peripheral nerve fascicles—across the amputation plane.2
2.2. Manufacturing and Quality Control
The manufacturing and quality control processes for the EBRS must comply with the unified regulatory framework for combination products.5 This necessitates strict adherence to CGMP requirements outlined in 21 CFR Part 4. Manufacturers must be able to readily identify and document compliance across all constituent parts, maintaining a stringent device quality system for the hardware and external unit, while simultaneously applying the necessary regulations governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) for the biological components.5
Specific quality controls include ensuring the sterility and purity of all biological components, rigorous assessment of cell viability and potency post-preparation, and maintenance of the integrity of the temporary scaffold device. Furthermore, ethical requirements demand that the protocol detail precise, minimally invasive tissue collection methods from the subject/donor and require comprehensive consent regarding tissue collection, storage, and potential long-term research use.8
2.3. Preparation, Administration, and Handling Procedures
The successful implementation of the EBRS requires meticulous standardization of pre-operative preparation. This includes the harvesting, processing, and loading of the cellular/biologic components into the EBRS scaffold system under sterile conditions immediately prior to the surgical procedure.
Administration involves a highly specialized, multi-stage surgical procedure. This encompasses the implantation of the internal scaffold, the meticulous surgical connection (anastomosis) of the proximal vascular and neural stumps to the guiding conduits within the scaffold, and the secure docking of the external simulator interface.9 Post-implantation, the Simulation Protocol defines the schedule and parameters of the EBRS activation. Phase I of this study is specifically designed to determine the initial intensity and duration of the biophysical stimulation, defining the protocol for potential dose escalation (Maximum Tolerated Stimulation Protocol, MTSP) based on subject tolerance and early biological response indicators.
SECTION 3: TRIAL OBJECTIVES AND ENDPOINTS
The ambitious nature of whole-limb regeneration dictates that the endpoints for this Phase I/II trial must prioritize immediate safety and biological feasibility before assessing long-term functional efficacy.11
3.1. Primary Objectives (Safety and Feasibility)
Safety (Phase I): The primary safety objective is to rigorously assess the overall incidence, severity, and definitive relatedness of Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Suspected Unexpected Serious Adverse Reactions (SUSARs) attributed to either the EBRS device or its biological components over the critical 12-month period following implantation.
Feasibility (Phase II Initiation): Given that true regeneration is biologically impossible without perfusion, the critical primary feasibility endpoint is defined as the confirmation of successful and sustained biological integration.9 This is specifically measured by demonstrating maintained vascular patency (absence of graft occlusion or failure) of the neo-vasculature within the regenerating tissue area at 6 months post-implantation.9 This metric serves as an essential gate, proving the biological possibility of the intervention, which is necessary before functional claims can be evaluated.
3.2. Secondary Objectives (Early Efficacy, Functional Recovery, Biological Integration)
Secondary objectives are designed to support the claim of efficacy by quantifying structural success and initial functional gains.11 These include:
Structural Regeneration: To provide quantitative evidence of tissue formation by measuring the volumetric growth and density of regenerated bone (osteogenesis) and skeletal muscle (myogenesis) within the regenerated arm segment, assessed at 12 and 24 months post-implantation.12
Neuro-Integration: To evaluate the extent of functional motor and sensory nerve regeneration, which is objectively quantified by improvements in Nerve Conduction Velocity (NCV) and the amplitude of Sensory Nerve Action Potentials (SNAP) and Compound Motor Action Potentials (CMAP) over time.10
Functional Recovery: To assess the improvement in upper extremity disability and symptom severity using standardized, validated questionnaires. The change from baseline in the Disability/Symptom Score of the DASH (Disabilities of the Arm, Shoulder, and Hand) questionnaire serves as a key measure of functional outcome.14
Quality of Life (QoL): To determine the impact of successful regeneration on the subject's overall health status and Quality of Life (QoL), addressing specific psychosocial domains known to be affected by limb loss.4
3.3. Exploratory Objectives (Immunomonitoring, Aesthetics, Long-term Metrics)
Exploratory endpoints focus on novel assessment techniques and long-term integration factors. These include monitoring for subclinical immunological activity and potential rejection markers 15, objectively quantifying scar quality, pigmentation, and tissue texture using validated assessment scales (Patient and Observer Scar Assessment Scale, POSAS) and non-invasive imaging systems (VISIA) 16, and assessing changes in phantom limb pain sensation and body image integration compared to baseline.4
SECTION 4: STUDY DESIGN AND METHODOLOGY
4.1. Trial Phase and Design
This study employs an adaptive Phase I/II, single-arm, open-label, interventional trial design.1 The adaptive nature permits the simultaneous assessment of safety and determination of the optimal biophysical stimulation parameters (Phase I) before enrolling a larger cohort for feasibility and early efficacy assessment (Phase II).2
Given the potential variability in individual subject response to the biophysical stimulation parameters, Phase I utilizes a standard 3+3 dose escalation cohort design. This methodology is employed to safely and systematically establish the Maximum Tolerated Stimulation Protocol (MTSP), which will then be utilized in the Phase II cohort expansion. Due to the high-risk, unprecedented nature of attempting whole-limb regeneration and the absence of an ethically and practically feasible sham surgical procedure for this level of intervention, the trial will not incorporate a control arm but will rely on rigorous comparison to the subject's own baseline status and established historical outcomes for severe limb loss.1
4.2. Duration of Intervention and Follow-up Schedule
The active Intervention Period is defined by the initial surgical implantation and the subsequent 12-month active EBRS simulation cycle, during which the majority of structural regeneration is expected to occur.18
Given the necessity to track long-term structural stability, immunological status, and potential delayed complications associated with novel regenerative therapies, a mandatory Long-Term Follow-up period of a minimum of five (5) years post-intervention is required. The monitoring intensity must be high, especially in the acute phase, due to the complexity of the intervention and the critical need for tight vascular management. Therefore, frequent monitoring (daily/weekly in the first month, then monthly up to 6 months) will be implemented to manage potential adverse events and critical parameters, such as anticoagulant stability.18
4.3. Subject Identification and Screening
Potential subjects will be identified through collaboration with specialized trauma and limb salvage centers. Comprehensive pre-intervention screening must be conducted, including detailed anatomical imaging, neurophysiological testing (NCV), validated functional scores, and extensive psychosocial evaluations. These assessments serve as the essential baseline against which the safety and efficacy of the EBRS intervention will be measured.
SECTION 5: SUBJECT SELECTION AND WITHDRAWAL CRITERIA
5.1. Inclusion Criteria
Subject selection must balance the clinical need with the requirements for successful biological integration of the EBRS. Key inclusion criteria are:
Age: Subjects must be 18 years or older at the time of signing informed consent.20
Condition: Documented severe, unilateral upper limb loss (e.g., traumatic transradial or transhumeral amputation) that is judged by a specialist surgical team to be not amenable to conventional reconstruction or replantation, or a severe congenital defect functionally equivalent to high-level amputation.
Prior Treatment Failure: Evidence that the subject has shown no sufficient response to best standard medical or surgical care delivered for at least six weeks, or documentation confirming that conventional surgical or radiological interventional options for revascularization have been exhausted.20
Vascular Status (Stump): Confirmation, via imaging, of patent and viable proximal vascular stumps capable of reliable microvascular anastomosis.
Consent and Compliance: The subject must exhibit the cognitive ability to fully comprehend the highly complex informed consent process and demonstrate willingness and capacity to comply with the rigorous post-operative monitoring schedule and intense rehabilitation regimen. Signed informed consent must be documented.20
Absence of Acute Threat: Absence of immediate life-threatening complications stemming from the ischemic limb or related trauma, if applicable.20
5.2. Exclusion Criteria
Exclusion criteria are critical for patient safety in this high-risk trial:
Co-morbidities: Presence of uncontrolled or life-threatening systemic diseases, such as severe, unstable cardiovascular disease or uncontrolled diabetes.20
Infection: Active systemic infection or uncontrolled localized infection at the intended surgical site.
Immunological Status: Subjects requiring long-term, high-dose systemic immunosuppression unrelated to the study components, unless allogeneic biological components are utilized, necessitating standard immunosuppression protocols.
Contraindications: Presence of contraindications to the necessary imaging procedures (e.g., MRI) or to the materials used in the EBRS device (e.g., metallic implants or pacemakers) or an inability to safely manage necessary pre-operative medication changes (e.g., stopping required anticoagulants).19 Specific management requirements dictate that anticoagulants like Coumadin (Warfarin) and Plavix (Clopidrogel) must be stopped seven days prior to surgery.19
5.3. Criteria for Discontinuation or Withdrawal
Subjects will be permanently withdrawn if they develop an irreversible Serious Adverse Event (SAE) directly attributable to the EBRS components, if there is catastrophic failure of the vascular supply leading to limb necrosis requiring acute re-amputation, or upon voluntary withdrawal of consent by the subject.
SECTION 6: STUDY PROCEDURES AND INTERVENTION
6.1. Pre-Intervention Screening and Baseline Assessments
A comprehensive assessment battery is required during the screening phase. This includes a detailed review of medical history, baseline laboratory analyses, immunological profiling (essential if allogeneic components are used), and baseline functional assessment. Objective measurements of functional dexterity utilizing the DASH score 14 and quantification of existing muscle/bone density in the residual limb using Dual-Energy X-ray Absorptiometry (DEXA) scans will be completed.13
6.2. Surgical Procedure for EBRS Implantation and Tissue Preparation
The surgical procedure is technically demanding and requires specialized planning. Strict Anticoagulation Management protocols must be followed: all anticoagulants, including but not limited to Coumadin, Plavix, and Effient, must be strictly managed and stopped according to regulatory standards and institutional guidelines (e.g., 7 days pre-op for Coumadin and Plavix) to minimize surgical bleeding risk while preventing pre-operative vascular thrombosis.19
The primary surgical objectives are Anastomosis and Scaffold Integration. This involves the meticulous connection of the proximal vascular stumps (arteries and veins) to the pre-loaded neo-vascular conduits within the EBRS scaffold system to ensure perfusion of the regenerating structure.9 Concurrently, Neural Coaptation must be performed, placing and coapting the major peripheral nerves (ulnar, median, radial) into specialized, guided channels within the scaffold to facilitate directed axonal regrowth, a prerequisite for functional movement and sensation.10
6.3. EBRS Activation and Regeneration Cycle Protocol
Post-operatively, the external simulator is activated according to the established Maximum Tolerated Stimulation Protocol (MTSP) derived from the initial Phase I cohort data. Biweekly monitoring of the stimulation parameters and subject tolerance is essential. Adjustments to the stimulation protocol may be necessitated based on clinical indicators, such as signs of tissue viability, vascular flow dynamics, or subject discomfort. The active regeneration phase using the EBRS is expected to span 12 months. Following confirmation of structural stability and integration, EBRS deactivation and removal of internal or external components will proceed as biologically feasible.
6.4. Post-Surgical Care and Rehabilitation Plan
Post-surgical care is intensive. The Acute Care phase (Days 1–14) requires continuous monitoring in a specialized unit, with strict adherence to post-operative anticoagulation therapy to maintain patency of the newly connected vascular structures.19 Wound management is critical; dressing changes commence 2 days after surgery, and staples or sutures are typically removed at the first post-operative office visit, approximately 2 weeks after surgery.19
The long-term success of the EBRS therapy is dependent upon a specialized, multi-phase Rehabilitation Plan. A regimen of physical and occupational therapy designed to maximize functional integration, motor control refinement, and sensory re-education must commence immediately post-discharge and continue indefinitely, guiding the newly formed tissues to achieve functional use.
SECTION 7: EFFICACY ASSESSMENTS AND OUTCOME MEASURES
The objective measurement of success in tissue engineering trials requires moving beyond subjective patient reporting to include quantifiable biological evidence of structure formation.
7.1. Primary Efficacy Measures (Feasibility Success Metrics)
The Primary Feasibility Endpoint (6 Months) is the measure of critical biological integration: sustained patency (defined as greater than 80% flow) of the primary engineered vascular conduits supplying the regenerating tissue, confirmed non-invasively via Doppler ultrasound or, if necessary, angiography.9 Successful completion of the trial is ultimately defined as the subject maintaining the regenerated tissue for at least 12 months without requiring amputation or suffering functional failure due to tissue necrosis, which confirms fundamental biological integration.
7.2. Functional Recovery Endpoints
Functional metrics assess the subject's ability to utilize the regenerated limb in activities of daily living. The primary functional endpoint is the change from baseline in the Disability/Symptom Score of the DASH questionnaire 14 at 12 and 24 months. Investigators must ensure standardized data collection, as a DASH score cannot be calculated if more than three items are missing.14
Further measures include the objective quantification of Muscle Strength, specifically handgrip strength, key pinch strength, and quantitative Maximum Voluntary Isometric Contraction (MVIC) of the regenerated forearm and hand musculature at 12 and 24 months.13 Exploratory functional measures, such as stair climbing power or the 6-Minute Walk Test (6MWT), may be collected to determine overall fitness and potential endpoints for future trials.13
7.3. Biological and Structural Endpoints
Structural integrity is quantified using advanced imaging techniques. Musculoskeletal Volumetrics involve quantitative assessment of total regenerated muscle volume and fat infiltration using automated segmentation algorithms applied to serial CT or MRI datasets.12 These methods solve the problem of time-dependent manual segmentation, allowing for rapid and accurate assessment of volume change from the baseline stump volume to the regenerated tissue volume at 12 and 24 months.12 Additionally, Bone Density of the regenerated segment is measured by Dual-Energy X-ray Absorptiometry (DEXA) scans at 12 and 24 months to confirm successful osteogenesis and skeletal load-bearing capacity.13
7.4. Neurovascular Integration Endpoints
Neurophysiological assessment provides direct evidence of functional nerve regeneration. Nerve Conduction Studies (NCS) must be performed pre-treatment and at 6 and 12 months. Key measurements include the Motor Nerve Conduction Velocity (MCV) and the Compound Motor Action Potential (CMAP) amplitude for motor function, and the Sensory Nerve Conduction Velocity (SCV) and Sensory Nerve Action Potential (SNAP) amplitude for sensory function.10 Methodological rigor requires strict standardization; NCS procedures must be conducted with precise temperature control (arm temperature maintained ideally between 30°C and 36°C) to prevent data distortion, as every 1°C of cooling can slow conduction velocity by 1.5 to 2.5 meters per second.10 Vascular integrity must be tracked via non-invasive imaging (Doppler, MRA) quarterly for two years to monitor long-term patency rates.9
7.5. Patient-Reported Outcomes (PROs) and Psychosocial Assessment
Patient-Reported Outcomes (PROs) provide crucial context for functional success. Quality of Life is assessed using the Short Form-36 (SF-36) questionnaire, evaluating changes in the physical (PCS) and mental (MCS) component summary scores at 12 and 24 months. Specific attention must be paid to domains significantly influenced by limb loss, such as Bodily Pain (BP) and Role Limitations due to Emotional Problems (RE).4 Furthermore, dedicated assessment of Body Image and Self-Esteem using validated instruments, such as the Rosenberg self-esteem scale, is necessary, as the presence of phantom pain sensation is known to significantly influence these psychosocial domains.4
Table 2: Efficacy Endpoints and Measurement Tools
Endpoint Category | Primary/Secondary | Specific Metric/Definition | Assessment Tool/Citation |
Feasibility (Primary) | Primary | Sustained vascular patency ( flow) in neo-conduits at 6 months. | Doppler Ultrasound/Angiography 9 |
Functional Dexterity | Secondary | Change in Disability/Symptom Score from baseline to 12 months. | DASH Questionnaire 14 |
Neuro-Integration | Secondary | Improvement in Motor NCV and SNAP amplitude (Temperature controlled). | Nerve Conduction Study (NCS) 10 |
Structural Volume | Secondary | Percent increase in regenerated muscle volume quantified via automated segmentation. | Quantitative MRI/CT Segmentation 12 |
Aesthetic Outcome | Exploratory | Scar quality, texture, color, and elasticity assessment. | POSAS (Patient and Observer Scar Assessment Scale) or VISIA imaging 16 |
QoL/Psychological | Secondary | Change in SF-36 Mental Health (MH) and Bodily Pain (BP) scores. | SF-36 Questionnaire 4 |
SECTION 8: SAFETY ASSESSMENTS AND ADVERSE EVENTS
8.1. Definition and Reporting
The safety assessment plan mandates strict adherence to established regulatory standards, including rigorous definition and expedited reporting timelines for AEs, SAEs, and SUSARs as mandated by ICH E6 guidelines. Expedited reporting for fatal or life-threatening events must occur within seven days of notification.
8.2. Scheduled Monitoring Procedures and Lab Tests
Routine monitoring includes comprehensive metabolic panels, complete blood counts, and specialized coagulation studies, which are essential due to the required use of anti-coagulation therapy necessary to prevent neo-vascular graft occlusion.19 Monitoring of infection markers (e.g., C-Reactive Protein, Procalcitonin) is also critical due to the risk associated with complex, implanted scaffolds.
8.3. Immunomonitoring Strategy
The use of extensive regenerative scaffolds and potentially allogeneic components, coupled with the high biological activity involved in regeneration, mandates an advanced immunological surveillance strategy that moves beyond standard clinical laboratories. The concern is that the host response to the non-self material (scaffold) and high biological activity may trigger a localized inflammatory or immune response that mimics allograft rejection.15
To detect subclinical rejection or destructive inflammatory activity at the scaffold site, the strategy includes tracking conventional inflammatory biomarkers (cytokine panels). More critically, an exploratory strategy involves the utilization of specialized molecular imaging. ImmunoPET, which employs antibodies conjugated to radioisotopes targeting surrogate biomarkers such as OX40 (a marker for alloreactive T cells), offers a noninvasive approach to visualize the dynamic distribution of immune cell infiltration within the regenerating tissue area.15 This technique, adapted from monitoring organ transplant rejection 15, is essential for diagnosing a localized, destructive immune response before it leads to catastrophic construct failure. Furthermore, protocolized tissue biopsy of the regenerating limb segment will be conducted upon clinical suspicion of scaffold rejection or non-integration.
8.4. Long-Term Surveillance Plan
The safety follow-up plan requires continuous surveillance for five years post-EBRS removal. This extended period is necessary to monitor for potential delayed toxicities, chronic pain development, mechanical failure of integrated structures, potential risks of malignancy associated with prolonged cellular and growth factor stimulation, and long-term immunological status.
Table 3: Key Subject Monitoring and Follow-up Schedule
Time Point | Intervention Phase | Key Safety Assessments | Key Efficacy Assessments |
Pre-Intervention | Screening/Baseline | Comprehensive lab panel, Imaging (CT/MRI), Psychological screening. | DASH, SF-36, Baseline NCS/Vascular flow. |
Day 1-14 | Acute Post-Op/Hospital | Daily monitoring of Vitals, Wound checks, Anticoagulation labs (PT/INR/aPTT). | Initial Vascular assessment, AE recording.19 |
Month 1, 3, 6 | Early Regeneration | Immunomonitoring (OX40/biomarkers), Clinical lab work, Focused physical exam. | DASH, Early functional mobility, Vascular patency checks.9 |
Month 12 | Primary Endpoint Check | Comprehensive safety review, Scar assessment (POSAS/VISIA). | Primary Feasibility check, Full NCS, Muscle Volume (MRI/CT), Strength.12 |
Month 24 | Functional Integration | Long-term AE tracking. | Full functional battery (DASH, Strength), Long-term QoL.4 |
Annually (Years 3-5) | Long-Term Surveillance | Monitoring for delayed complications/graft stability. | Functional stability, Body image assessment. |
SECTION 9: STATISTICAL CONSIDERATIONS
9.1. Sample Size Justification
Due to the highly experimental nature and high risk profile of whole-limb regeneration, the sample size for this Phase I/II trial is not driven by traditional statistical power calculations for functional superiority. Instead, the size is determined by the requirements for demonstrating safety and clinical feasibility.11
The Phase I Cohort will utilize a small cohort (N=3–6) to safely and systematically establish the MTSP and confirm acute safety margins. The Phase II Cohort will expand the enrollment (target N=10–15 total subjects) and will be powered primarily to achieve a pre-specified success rate for the primary feasibility endpoint—sustained vascular patency at 6 months. The sample size calculation will focus on achieving a sufficient statistical precision (e.g., an 80% success rate with a narrow confidence interval) to demonstrate that the complex surgical and biological intervention is achievable and sustainable.
9.2. Statistical Methods for Primary and Secondary Endpoints
The Primary Safety Analysis will rely on descriptive statistics, reporting the number (N) and percentages of all TEAEs, stratified rigorously by severity (Common Terminology Criteria for Adverse Events, CTCAE) and definitive relationship to the investigational product.
The Primary Feasibility Analysis will calculate the success rate, defined as the proportion of subjects achieving sustained vascular patency at 6 months, accompanied by the calculation of exact 95% confidence intervals. Secondary efficacy endpoints, such as changes in the DASH score, NCV parameters, and muscle volume (using quantitative imaging), will be analyzed using paired statistical methods, such as paired t-tests or Wilcoxon signed-rank tests, comparing the changes from baseline to the 12- and 24-month follow-up visits.
SECTION 10: ETHICAL, DATA MANAGEMENT, AND REGULATORY COMPLIANCE
10.1. Ethical Conduct and Informed Consent Process
The trial must be conducted in strict adherence to the fundamental ethical principles stipulated in the Declaration of Helsinki and the requirements of Good Clinical Practice (GCP, ICH E6 R2/R3). Given the experimental nature of whole-limb regeneration, the Informed Consent Process must be exhaustive, transparent, and non-coercive.
The consent form requires specific, detailed articulation of high-level ethical considerations.8 This includes transparent disclosure of the following: The highly experimental status of the EBRS and the feasibility-focused nature of the trial, acknowledging that functional success is not guaranteed; The specific methodology for tissue collection, handling, and storage required for the biological constituent parts, emphasizing that methods are designed to be minimally harmful to the donor; Full disclosure concerning the long-term storage and future use of the regenerated tissues and associated biological data for ongoing research and development ; and Explicit transparency regarding any possible financial interests, intellectual property claims, or potential future commercial value the sponsor may derive from the EBRS technology or the resultant regenerated tissue.
10.2. Quality Assurance and Quality Control
Quality assurance will be maintained through comprehensive oversight. An Independent Data Monitoring Committee (DMC) will be established to provide objective review of accumulating safety data, particularly during the critical Phase I dose escalation, and to monitor early efficacy trends. Regular monitoring and auditing of the trial site are mandatory to ensure complete source data verification, adherence to the specific procedural details of the protocol, and continued compliance with the CGMP requirements relevant to both device and biologic components.
10.3. Institutional Review Board (IRB)/Ethics Committee Submission
Finalization of the protocol, Investigator Brochure (IB), and all informed consent documents requires submission to and documented approval by the relevant Institutional Review Board (IRB) or Ethics Committee prior to the initiation of any subject screening or enrollment. This submission must ensure that the nuanced ethical requirements regarding tissue use and financial transparency have been adequately addressed and reviewed.
Conclusions and Recommendations
The proposed Phase I/II clinical trial protocol for the Enhanced Biological Regeneration Simulator (EBRS) addresses the high scientific and regulatory hurdles associated with whole-limb regeneration. The successful execution of this protocol depends on several critical factors:
Regulatory Precision: The explicit definition of the EBRS as a combination product with a Biologic/Tissue Engineering PMOA, targeting CBER as the lead review center while fully adhering to 21 CFR Part 4 CGMP requirements, is paramount for securing regulatory approval and utilizing expedited pathways like RMAT.6
Feasibility Prioritization: Given the unprecedented nature of the intervention, the protocol correctly identifies the primary measure of success as biological feasibility, specifically sustained vascular patency at 6 months.9 Failure to achieve robust perfusion renders subsequent functional measures irrelevant.
Objective Efficacy Metrics: Efficacy assessment must rely heavily on objective, quantitative measures that prove structural reconstruction, including volumetric analysis of muscle and bone via advanced CT/MRI segmentation and functional confirmation of neural repair through standardized, temperature-controlled Nerve Conduction Studies (NCV).
Rigorous Safety Monitoring: The high-risk status necessitates intensive acute post-operative care, including strict anticoagulant management , and the inclusion of advanced immunological surveillance strategies (e.g., ImmunoPET targeting OX40) to detect subclinical immune activity against the construct.
It is recommended that the sponsor ensures sufficient resources are allocated to the specialized surgical training and the protracted five-year safety follow-up period, as mandated for novel regenerative therapies. Furthermore, continuous dialogue with regulatory bodies regarding the proportionality of risk management, particularly concerning the ethical disclosure of intellectual property related to the regenerated tissue, will be necessary to ensure maximum compliance and transparency.
import numpy as np
ความคิดเห็น
แสดงความคิดเห็น